| Background: Y-box binding protein-1(YB-1) is one of the member of the cold shock protein family and plays an important role in regulating cellular functions. Researches have shown that YB-1 was closely related to the clinicopathological characteristics and prognosis in a variety of malignant tumor. But the specific role of YB-1 in cancer is still unclear. Therefore, our study took the breast cancer(BC) as the research object. We assessed the value of YB-1 in the clinicopathological characteristics and prognosis of BC patients using a meta-analysis based on the published studies.Methods: We searched the relevant literatures deadline for March 2015 in some electronic databases, including Pubmed, Embase, Medline and Cochrane library. A meta-analysis method was conducted with eligible studies to evaluate the relationship of YB-1 overexpression with the clinicopathological characteristics and prognosis of patients with BC. The results included:(1) Combined odds ratio(OR) and 95% confidence interval(95% CI) were used to evaluate the relationship between YB-1 expression and clinicopathological parameters.(2) Aggregated relative risk(RR) and 95% CI through indirectly calculating were performed to assess the impact of YB-1 expression on 5 year overall survival(OS) rate in BC patients.(3) The heterogeneity was evaluated by the Q-test and P-values.(4) Begg’s funnel plot and homologous P-values were used to evaluate the publication bias in the literatures included.(5) Sensitivity analysis was used to test whether any one study had an obvious impact on the overall results.Results: A total of 8 eligible studies were included in our study which contained 1094 BC patients with 398 YB-1 positive and 696 YB-1 negative. Combined OR and 95% CI showed that YB-1 expression was statistically associated with the factors which affected the prognosis of BC. The results included:(1) The expression of YB-1 was negatively correlated with the expression of estrogen receptor(ER) [OR= 0.604, 95%CI= 0.388-0.941, P= 0.026]. The expression of YB-1 was positively correlated with human epidermal growth factor receptor type 2(HER2) [OR= 3.841, 95%CI= 2.637-5.594, P= 0.000]. The expression of YB-1 was positively correlated with tumorous T stage [OR= 2.169, 95%CI= 1.295-3.632, P= 0.003].(2) The expression of YB-1 was not significantly related with lymph node status [OR= 1.258, 95%CI= 0.895-1.769, P= 0.186], histological grade [OR= 2.709, 95%CI= 0.861-8.530, P= 0.089], histological type [OR= 0.837, 95%CI= 0.526-1.331, P= 0.452], tumor suppressor gene P53 status [OR= 2.006, 95%CI= 0.686-5.865, P= 0.203], progesterone receptor(PR) [OR= 0.607, 95%CI= 0.347-1.061, P= 0.080].(3) Aggregated RR and 95% CI showed that YB-1 expression had an adverse impact on 5 year OS in BC patients [RR= 2.767, 95%CI= 2.054-3.727, P= 0.000].Conclusions:(1) YB-1 was overexpression in some BC tissues. It could affect the expression of some molecules related with BC, such as ER and HER2.(2) YB-1 could affect the tumorous T stage and 5 year OS in BC patients. It can be considered as one of the monitoring indexes in evaluating the prognosis of BC. YB-1 will become a new target and molecular marker in BC treatment and prognosis assessment. |
PDF Full Text Request